Cabazitaxel NEW

Cabazitaxel is a microtubule inhibitor that is indicated in combination with Prednisone or Prednisolone for the treatment of patients with metastatic prostate cancer who are refractory to treatment with previous Docetaxel containing docetaxel treatment regimens. More precise treatment is achieved throughout the treatment process. It acts by disrupting the microtubule network that is essential for mitotic and interphase cell function and causes inhibition of cell division and cell death. Cabazitaxel has been shown to inhibit cell division and tumor cell proliferation by binding to and stabilizing tubulin, the proteins in cell microtubules that provide the skeleton that maintains the cell's shape.

indication

Cabazitaxel is a microtubule inhibitor that is indicated in combination with Prednisone or Prednisolone for the treatment of hormone refractory metastatic prostate cancer in patients who have been treated with Docetaxel containing docetaxel. Carbataxel Jevtana can inhibit cancer cell growth and even cause cancer cell death. Clinical trials have shown that it can also shrink tumors and slow the growth or spread of tumors to relieve symptoms of prostate cancer and improve patients' quality of life.

Pharmacological action

The anti-cancer mechanism and characteristics of carbataxel are similar to docetaxel, and carbataxel belongs to the class of anti-microtubule drugs. Kappa him through combined with tubulin, kappa he promote its assemble into microtubules, at the same time kappa he has assembled the game can stop the microtubule disassembly, kappa his game that stabilize microtubules, kappa he thereby inhibiting cell mitosis, and interphase cell function (interphasecellularfunctions).

Application:

1 Cabazitaxel is used in combination with prednisone for the treatment of hormone-resistant metastatic prostate cancer previously treated with docetaxel-containing regimens.

2 Signal transduction pathway kinase inhibitors.